A Phase 1/2A Multicenter, Open-Label Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs LYC 55716 (Primary)
- Indications Bladder cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Renal cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Acronyms ARGON
- Sponsors Lycera
- 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium
- 04 Jan 2018 According to a Lycera media release, interim findings expected by the second half of 2018.
- 16 Nov 2017 Planned number of patients changed from 90 to 105.